Last reviewed · How we verify
Fidia Farmaceutici s.p.a. — Portfolio Competitive Intelligence Brief
3 marketed
0 filed
0 Phase 3
1 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Liposom Forte | Liposom Forte | marketed | ||||
| Itami | Itami | marketed | Other | |||
| Tricortin 1000 | Tricortin 1000 | marketed | ACTH analog | Melanocortin-2 receptor (MC2R) | Endocrinology |
Therapeutic area mix
- Endocrinology · 1
- Other · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Attune Health Research, Inc. · 1 shared drug class
- NYU Langone Health · 1 shared drug class
- University of Colorado, Denver · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Fidia Farmaceutici s.p.a.:
- Fidia Farmaceutici s.p.a. pipeline updates — RSS
- Fidia Farmaceutici s.p.a. pipeline updates — Atom
- Fidia Farmaceutici s.p.a. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Fidia Farmaceutici s.p.a. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fidia-farmaceutici-s-p-a. Accessed 2026-05-17.